Exelixis (NasdaqGS:EXEL) Reports Positive Phase 3 Trial Results For Colorectal Cancer

Exelixis (NasdaqGS:EXEL) recently announced positive topline results from the STELLAR-303 Phase 3 trial, highlighting the effectiveness of zanzalintinib in combination with atezolizumab for treating certain colorectal cancers, which likely fueled its 24% share price increase over the last quarter. The company's strong financial performance, including significant revenue and net income growth, likely provided additional support to this positive momentum. Market conditions were generally favorable, with a 12% increase over the past year, and Exelixis's price movement significantly exceeded this broader trend, indicating strong investor confidence in its latest developments.

Exelixis has 1 weakness we think you should know about.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

The recent positive topline results from Exelixis's STELLAR-303 Phase 3 trial could significantly bolster its narrative of strong growth prospects. This achievement has aided the company’s short-term share price gain, yet it's essential to consider its longer-term performance. Over the past three years, Exelixis has achieved a total shareholder return of 119.91%, showcasing substantial growth beyond the recent quarterly increase. This period highlights the firm's consistent value delivery to shareholders.

In the past year, Exelixis's share price outperformed the broader US market, which saw a 12.2% increase, and also exceeded the US Biotechs industry, which experienced a 10.4% decline. The recent news fortifies expectations for revenue and earnings growth, anticipating a considerable market expansion for CABOMETYX through potential approvals for new indications, particularly for neuroendocrine tumors. Analysts forecast a 9.7% annual revenue growth, with projected earnings of US$943 million by 2028, aligning with strategic market expansion endeavors.

Despite the recent rise in share price, it remains below the analyst consensus price target of US$38.05. This suggests there is still a 3.1% potential upside, indicating that the current price of US$36.86 could be undervaluing the company's future prospects. The alignment or divergence from these projections can substantially influence investor sentiment and future share price movements, making ongoing assessment vital for stakeholders.

Click here to discover the nuances of Exelixis with our detailed analytical financial health report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com